Skip to main content
Premium Trial:

Request an Annual Quote

Fulgent Genetics Makes $19M Investment in Chinese JV, Takes Controlling Interest

NEW YORK — Fulgent Genetics said on Monday that it has made a roughly $19 million investment in FF Gene Biotech, giving it controlling ownership of the Chinese genetic testing joint venture.

Fulgent formed FF Gene Biotech in 2017 with Xilong Scientific and Fuzhou Jinqiang Investment Partnership in order to establish a presence in China for its sequencing-based genetic testing services, with a focus on the cancer, reproductive health, and pediatric markets.

In a recent filing with the US Securities and Exchange Commission, Fulgent said that it has, to date, contributed $4.5 million in equipment to FF Gene Biotech but determined that the joint venture lacks the capital necessary to operate independently.

Following its latest investment in FF Gene Biotech, Fulgent said it intends to increase testing capacity at the joint venture's Fujian-based facility and expand its sales organization. Fulgent noted that since it was formed, FF Gene Biotech has generated revenues of more than $10 million on test volume of more than 50,000.

Fulgent also said that it will now recognize the financial impact of FF Gene Biotech within its consolidated financial results. The transition is expected to close in the second quarter.

"Our incremental investment in FF Gene Biotech is an important strategic milestone for Fulgent Genetics as we look to expand our presence on the ground in China," said Ming Hsieh, Fulgent's chairman and CEO, in a statement. "We see a significant market opportunity for NGS testing in China, and we believe that our differentiated approach to testing with our scalable technology platform, efficient lab operations, expansive test menu, and superior customer service will make us well positioned to capitalize on this opportunity."

Earlier this month, Temple City, California-based Fulgent reported strong first quarter revenue growth on demand for its SARS-CoV-2 testing services.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.